The U.S. FDA approved Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma
On Jan. 30, 2012, the U.S. Food and Drug Administration (FDA) approved Genentech’s Erivedge (vismodegib) capsule, the first…
Yale Cancer Center was awarded a SPORE (Specialized Programs of Research Excellence) grant for translational research
On Oct. 10, 2006, Yale Cancer Center was awarded a SPORE (Specialized Programs of Research Excellence) grant for…